backgroundpurpos
serum
solubl
trigger
receptor
express
myeloid
detector
acut
inflammatori
respons
microbi
product
good
marker
diagnos
sepsi
pneumonia
yet
describ
predictor
infect
prognost
factor
patient
acut
respiratori
distress
syndrom
ard
method
prospect
observ
cohort
studi
enrol
ventil
adult
patient
ard
septic
nonsept
follow
day
intens
care
unit
univers
hospit
taiwan
serial
serum
level
cytokin
interleukin
il
tumor
necrosi
day
measur
enzymelink
immunosorb
assay
associ
biomark
clinic
infecti
diagnosisoutcom
ard
explor
result
serum
cytokin
level
could
differenti
septic
nonsept
ard
serum
log
inflammatori
cytokin
level
correl
posit
r
r
r
tumor
necrosi
prognost
factor
higher
serum
level
day
increas
level
time
especi
first
day
independ
predictor
mortal
day
use
multivari
cox
regress
model
serum
level
remain
stabl
even
increas
nonsurviv
patient
decreas
survivor
conclus
serum
level
might
reliabl
marker
infect
ard
patient
howev
inflammatori
marker
initi
serum
level
trend
time
especi
first
day
could
predict
shortterm
mortal
progress
declin
serum
level
followup
indic
favor
outcom
wherea
persist
elev
indic
poor
prognosi
lead
reevalu
therapi
acut
respiratori
distress
syndrom
ard
devast
clinic
condit
high
morbid
mortal
septic
nonsept
etiolog
sepsi
common
caus
wors
prognosi
compar
risk
factor
discrimin
septic
nonsept
caus
ard
import
prompt
physician
start
multimod
treatment
sever
sepsi
includ
use
recombin
human
activ
protein
c
earli
possibl
also
encourag
feel
free
use
corticosteroid
therapi
fibroprolif
phase
ard
without
ongo
infecti
process
howev
prompt
correct
diagnosi
septic
ard
difficult
mani
infecti
clinic
featur
chang
bodi
temperatur
leukocytosi
tachycardia
nonspecif
serum
biolog
marker
indic
sever
bacteri
infect
would
use
situat
mani
inflammatori
biomark
studi
differenti
septic
nonsept
ard
fulfil
requir
trigger
receptor
express
myeloid
recent
identifi
infecti
marker
transmembran
glycoprotein
consist
singl
extracellular
immunoglobulinlik
domain
transmembran
region
short
cytoplasm
tail
receptor
express
neutrophil
macrophagesmonocyt
main
effector
cell
innat
respons
trigger
amplifi
inflammatori
respons
presenc
gramposit
gramneg
bacteria
well
fungi
express
greatli
upregul
neutrophil
monocyt
hardli
express
noninfecti
inflammatori
diseas
psoriasi
ulcer
coliti
vascul
granulomat
disord
solubl
transmembran
intracellular
domain
releas
activ
phagocyt
found
bodi
fluid
previou
studi
presenc
bronchoalveolar
fluid
shown
good
indic
lung
infect
addit
serum
shown
abl
distinguish
survivor
nonsurvivor
sepsi
howev
inform
diagnost
role
infecti
marker
ard
patient
lack
therefor
design
clinic
observ
studi
investig
whether
new
inflammatori
marker
differenti
septic
nonsept
ard
addit
investig
serial
chang
well
serum
cytokin
level
il
interleukin
tumor
necrosi
factor
tnf
ard
patient
associ
clinic
outcom
patient
exclud
year
age
pregnant
treat
corticosteroid
mg
kg
equival
prednisolon
bone
marrow
organ
transplant
recipi
neutropenia
absolut
neutrophil
count
acquir
immun
defici
syndrom
note
studi
approv
nation
taiwan
univers
hospit
institut
review
board
inform
consent
patient
rel
obtain
enrol
upon
enrol
demograph
laboratori
characterist
collect
present
tabl
death
length
icu
stay
outcom
period
also
record
septic
nonsept
etiolog
retrospect
determin
accord
decis
clinic
attend
physician
definit
american
colleg
chest
physician
societi
critic
care
medicin
consensu
confer
committe
septic
group
base
presum
identifi
sourc
infect
combin
sign
system
inflammatori
respons
syndrom
sir
within
septic
group
patient
caus
microbi
pathogen
defin
pathogenconfirm
septic
group
patient
nonsept
group
sir
without
searchabl
infecti
focu
patient
manag
accord
surviv
sepsi
campaign
guidelin
symptom
sir
defin
previous
durat
sir
enrol
record
caus
pathogen
defin
organ
cultur
grown
normal
steril
bodi
fluid
tissu
intracellular
organ
phagocytos
polymorphonuclear
cell
seen
microscop
examin
sputum
specimen
urin
streptococcu
pneumonia
antigen
viru
use
polymeras
chain
reaction
detect
herp
simplex
viru
dna
serolog
analysi
level
measur
use
enzymelink
immunosorb
assay
elisa
r
system
minneapoli
mn
usa
serum
determin
use
cytokinespecif
elisa
accord
manufactur
protocol
r
system
measur
perform
duplic
previou
studi
serum
level
highsensit
creactiv
protein
crp
measur
latexparticleenhanc
immunoturbidimetr
assay
serum
cytokin
level
day
measur
ard
day
defin
day
patient
fulfil
ard
criteria
day
enrol
clinic
attend
physician
member
primari
care
team
blind
data
nonsurviv
patient
serum
cytokin
level
follow
death
descript
result
continu
variabl
express
median
interquartil
rang
cytokin
level
transform
log
valu
variabl
test
comparison
differ
group
use
pearson
test
fisher
exact
test
categor
data
nonparametr
test
mannwhitney
u
test
numer
data
statist
correl
calcul
spearman
nonparametr
coeffici
r
adjust
baselin
differ
use
univari
gener
linear
model
set
age
lung
injuri
score
li
covari
possibl
confound
factor
elev
serum
analyz
multivari
logist
regress
clarifi
effect
septic
etiolog
surviv
analysi
perform
use
kaplanmei
method
logrank
test
multivari
analys
perform
use
cox
proportionalhazard
regress
model
mortal
confid
interv
ci
enter
model
continu
variabl
transform
categor
binari
valu
use
median
valu
trend
cytokin
time
repres
slope
regress
line
multipl
time
point
analys
done
spss
version
spss
chicago
il
usa
p
valu
signific
twotail
test
use
studi
prospect
studi
patient
admit
medicalburnssurg
icu
survey
month
sixtythre
ard
patient
fulfil
inclus
criteria
enrol
patient
baselin
characterist
studi
group
shown
tabl
septic
pathogenconfirm
septic
nonsept
group
age
li
score
significantli
differ
crp
level
significantli
higher
septic
group
p
show
increas
trend
pathogenconfirm
septic
nonsept
group
p
enrol
differ
observ
serum
log
level
septic
nonsept
group
p
true
serum
log
cytokin
level
tabl
adjust
baselin
age
li
durat
sir
enrol
still
signific
differ
serum
log
valu
septic
nonsept
group
p
among
patient
whose
durat
sir
enrol
hour
serum
log
level
differ
patient
septic
group
nine
nonsept
group
p
correl
note
serum
log
level
enrol
initi
pao
fio
ratio
absolut
neutrophil
count
crp
level
except
log
r
p
r
p
pathogenconfirm
septic
group
elev
especi
gramneg
pathogen
figur
statist
signific
observ
use
multivari
logist
regress
model
adjust
possibl
confound
factor
includ
histori
gouti
arthriti
malign
abdomin
surgeri
past
month
presenc
pancreat
li
durat
sir
enrol
age
septic
etiolog
ard
found
independ
factor
elev
serum
log
valu
ci
p
overal
patient
ard
die
day
mortal
rate
concurr
predict
risk
death
base
acut
physiolog
chronic
health
evalu
apach
ii
sequenti
organ
failur
assess
sofa
score
mean
standard
deviat
respect
clinic
laboratori
data
survivor
nonsurvivor
list
tabl
nonsurvivor
younger
longer
drink
histori
survivor
p
surviv
analysi
show
younger
age
histori
chronic
liver
diseas
higher
baselin
sever
score
sofa
apach
ii
associ
higher
mortal
rate
sepsi
multipl
organ
failur
common
caus
shortterm
mortal
die
respiratori
failur
univari
analysi
serum
log
level
day
could
use
prognost
factor
mortal
day
p
could
log
cytokin
level
use
tabl
higher
serum
crp
level
howev
note
nonsurvivor
p
serum
log
level
posit
correl
log
r
p
log
r
p
log
level
r
p
analyz
durat
cours
ci
mean
valu
serum
log
time
plot
figur
nonsurvivor
baselin
serum
log
level
higher
trend
increas
time
especi
first
day
slope
regress
line
multipl
time
point
confirm
phenomenon
serum
log
level
p
tabl
multivari
cox
regress
model
age
year
p
presenc
chronic
liver
diseas
p
higher
baselin
apach
ii
score
p
higher
initi
sofa
score
p
remain
independ
factor
predict
mortal
day
tabl
regard
cytokin
day
serum
log
level
p
progress
increas
time
serum
log
level
p
log
level
p
independ
factor
serum
one
promis
paramet
differenti
sepsi
sir
accord
previou
studi
howev
studi
serum
level
day
ard
could
differenti
septic
nonsept
group
critic
ill
patient
univari
multivari
analysi
adjust
possibl
confound
factor
recent
major
abdomin
surgeri
pancreat
activ
malign
gouti
arthriti
show
septic
etiolog
ard
associ
elev
serum
log
level
moreov
consid
durat
sir
septic
nonsept
group
onset
ard
seem
affect
serum
log
level
accord
univari
multivari
subgroup
analys
patient
whose
durat
sir
enrol
hour
result
depart
find
sepsi
report
gibot
et
al
could
explain
follow
first
ard
induc
direct
lung
injuri
might
higher
concentr
lung
serum
pulmonari
infect
aspirationrel
ard
might
lower
level
serum
although
classifi
septic
ard
second
recent
clinic
studi
investig
role
infecti
diagnosi
shown
good
marker
infect
sepsi
ventilatorassoci
pneumonia
critic
ill
patient
explain
discrep
propos
follow
differ
sensit
assay
elisa
immunoblot
exposur
antibiot
lack
thereof
inadequ
control
absenc
suspect
infect
among
patient
group
variou
studi
third
limit
case
number
retrospect
definit
nonsept
ard
might
compromis
diagnost
valu
infect
although
serum
might
suitabl
infecti
marker
ard
still
note
pathogenconfirm
septic
ard
patient
serum
higher
cultur
grew
gramneg
bacilli
pseudomona
aeruginosa
klebsiella
pneumonia
escherichia
coli
patient
gramposit
coccal
fungal
viral
infect
serum
level
lower
howev
signific
differ
instead
serum
level
infecti
marker
find
suggest
prognost
factor
multivari
analysi
higher
serum
log
level
day
increas
trend
serum
log
level
time
especi
first
day
associ
unfavor
outcom
comparison
level
septic
patient
find
line
gibot
et
al
determann
et
al
show
progress
declin
serum
surviv
patient
especi
first
day
furthermor
result
show
signific
posit
correl
serum
log
inflammatori
cytokin
level
abovement
result
elev
serum
level
ard
patient
indic
sever
inflamm
induc
higher
mortal
rate
infect
first
day
serum
elev
ard
compat
acut
exud
phase
alveolar
macrophag
neutrophil
recruit
alveolar
space
cytokin
releas
prognost
find
ard
patient
similar
sepsi
studi
gibot
et
al
intervent
need
elev
serum
log
level
especi
first
day
followup
indic
progress
system
inflammatori
respons
data
clarifi
inflammatori
marker
albeit
good
infecti
one
find
confirm
higher
sofa
apach
ii
score
associ
poor
prognosi
result
previou
studi
howev
age
year
studi
anoth
prognost
factor
unfavor
outcom
might
due
longer
drink
histori
younger
patient
alcohol
abus
thought
associ
high
mortal
ard
patient
accord
studi
wakabayashi
et
al
addit
persist
elev
trend
serum
might
predict
poor
prognosi
multivari
analysi
tabl
also
found
previou
ard
studi
goodman
et
al
regard
serum
crp
level
studi
might
use
differenti
septic
nonsept
ard
patient
even
better
serum
barati
et
al
report
phenomenon
crp
perform
better
diagnos
infect
barati
et
al
howev
note
diagnost
accuraci
sepsi
marker
highli
depend
set
test
studi
conduct
heterogen
group
icu
patient
similar
ard
group
consist
variou
caus
etiolog
heterogen
popul
small
number
patient
might
reason
differ
diagnost
valu
crp
analysi
prognost
valu
although
higher
serum
crp
level
observ
nonsurvivor
univari
analysi
effect
seen
multivari
analysi
tabl
could
shortterm
mortal
correl
better
inflammatori
variabl
level
serum
cytokin
serum
crp
level
sever
limit
present
studi
first
number
patient
small
nonsept
group
patient
enrol
base
data
post
hoc
power
analysi
clinic
trial
clarifi
diagnost
valu
serum
level
infect
estim
requir
patient
group
statist
power
signific
criterion
second
analyz
inflammatori
marker
procalcitonin
check
crp
day
follow
cours
ard
third
investig
presenc
peptic
ulcer
diseas
use
panendoscopi
due
ethic
sensit
critic
patient
present
activ
gastrointestin
bleed
peptic
ulcer
diseas
could
potenti
elev
level
final
least
nonsept
ard
group
studi
defin
retrospect
review
could
compromis
conclus
diagnost
valu
sepsi
possibl
occult
infect
group
could
rule
clinic
precis
prospect
identif
nonsept
ard
difficult
sepsi
alway
consid
caus
differenti
diagnosi
lethal
adequ
treatment
taken
larg
studi
includ
detect
inflammatori
marker
warrant
confirm
result
summari
serum
level
might
reliabl
marker
differenti
septic
nonsept
ard
patient
inflammatori
marker
could
provid
use
predictor
shortterm
mortal
especi
followup
level
increas
first
day
declin
serum
level
treatment
indic
improv
contrari
persist
elev
serum
level
lead
reevalu
treatment
manag
